VivePeptides logo

Research Use Only

Growth Hormone Peptides

GHRH analogs and growth-hormone secretagogues studied for their action on the somatotropic axis.

Growth Hormone Peptides are research compounds studied for their capacity to modulate the somatotropic axis through distinct receptor-level mechanisms. This category encompasses GHRH analogs, growth hormone releasing peptides, and IGF-1 analogs, each investigated in preclinical models for interactions with pituitary signaling pathways and downstream growth factor systems. All compounds are intended for laboratory research use only.

Reviewed by the VivePeptides Research DeskLast reviewed

Research Catalog

Compounds in this collection

Sermorelin research peptide vial

Sermorelin

$79.00View
CJC 1295 No DAC + Ipamorelin Blend research peptide vial

CJC 1295 No DAC + Ipamorelin Blend

$90.00View
Tesamorelin research peptide vial

Tesamorelin

$69.00View
IGF-1LR3 research peptide vial

IGF-1LR3

$109.00View

Research Overview

Growth Hormone Peptides: Research Category Overview and Compound Classes

The growth hormone peptide category encompasses synthetic analogs and mimetics that interact with the hypothalamic-pituitary somatotropic axis at distinct regulatory points. It represents one of the most investigated areas in peptide research, driven by preclinical examination of GH secretion dynamics, IGF-1 receptor signaling, and downstream effects on metabolic and tissue modeling systems. VivePeptides supplies four characterized compounds in this category, each representing a different mechanism class.

Sermorelin is a truncated GHRH analog corresponding to the first 29 residues of endogenous growth hormone releasing hormone. CJC 1295 No DAC combined with Ipamorelin is a dual-mechanism blend pairing a GHRH analog with a selective ghrelin receptor agonist and growth hormone releasing peptide. Tesamorelin is a stabilized full-length GHRH analog studied for enhanced structural integrity relative to shorter GHRH fragments.

IGF-1 LR3 is a long-acting IGF-1 analog operating downstream of the pituitary axis at peripheral growth factor receptors. All compounds are provided for in vitro and preclinical research use only.

Three Distinct Mechanism Classes

This collection spans GHRH analogs, a ghrelin receptor agonist, and an IGF-1 analog, giving researchers tools to interrogate separate nodes of the somatotropic axis within a single curated supplier relationship. Compound selection can be matched to the specific receptor system under investigation.

Upstream and Downstream Signaling Tools

GHRH analogs and growth hormone releasing peptides act at the pituitary level to stimulate GH secretion, while IGF-1 LR3 acts peripherally at IGF-1 receptors independent of pituitary input. This structural range in the collection allows researchers to study different layers of the growth factor cascade within a consistent quality framework.

Compound Selection for Study Design

Researchers differentiate growth hormone peptides by receptor target, structural half-life, and intended model system. Shorter GHRH analogs suit pulsatile secretion studies, dual-mechanism blends support synergy investigations, and downstream IGF-1 analogs are used when pituitary-independent receptor activation is the research variable.

Compound Comparison

How these compounds compare

CompoundMechanism ClassResearch FocusDistinguishing Feature
SermorelinGHRH analog (truncated fragment)Pituitary GH secretion kinetics29-amino acid minimal GHRH sequence
CJC 1295 No DAC + Ipamorelin BlendDual: GHRH analog plus ghrelin receptor agonistSynergistic GH axis receptor stimulationTwo-receptor mechanism, single preparation
TesamorelinFull-length stabilized GHRH analogGHRH receptor binding and GH release44-amino acid structure with enhanced stability
IGF-1 LR3IGF-1 analog (long-acting variant)Peripheral IGF-1 receptor activationBypasses pituitary, extended half-life profile

Mechanism & Research Context

Mechanism Classes and Preclinical Research Context for GH Peptides

The compounds in this growth hormone secretagogue collection are distinguished by where each acts within the somatotropic signaling cascade. GHRH analogs such as Sermorelin and Tesamorelin bind the GHRH receptor on pituitary somatotroph cells, initiating GH secretion through an adenylyl cyclase-coupled pathway.

The CJC 1295 No DAC and Ipamorelin blend introduces a second receptor class: Ipamorelin acts at the ghrelin receptor (GHS-R1a), engaging a separate intracellular signaling mechanism that preclinical literature has examined for synergistic interaction with GHRH receptor stimulation. IGF-1 LR3 bypasses the pituitary entirely, acting directly at IGF-1 receptors in peripheral tissues and representing a downstream research tool distinct in positional logic from the secretagogue compounds.

Preclinical investigations have applied these compounds to models of GH secretion kinetics, receptor selectivity profiling, and growth factor receptor activation studies. Researchers selecting among these gh peptides typically differentiate on the basis of target receptor, structural half-life, and intended placement within the somatotropic axis, with study design considerations including peptide stability, reconstitution protocol, and in vitro versus in vivo model requirements.

Research FAQ

Frequently asked questions

What are growth hormone peptides in a research context?

Growth hormone peptides are synthetic compounds studied in preclinical models for their capacity to modulate the somatotropic axis, either by stimulating pituitary GH secretion through GHRH or ghrelin receptor pathways or by acting directly at IGF-1 receptors in peripheral tissues. The category includes GHRH analogs, growth hormone releasing peptides, and IGF-1 analogs, each interacting with a distinct receptor class. These compounds are supplied for laboratory research use only and are not intended for human or veterinary application.

What is the mechanistic difference between a GHRH analog and a growth hormone releasing peptide?

GHRH analogs bind the GHRH receptor on pituitary somatotroph cells to stimulate GH secretion through the adenylyl cyclase pathway, while growth hormone releasing peptides such as Ipamorelin act as ghrelin receptor agonists at GHS-R1a, a structurally unrelated receptor population with a distinct intracellular signaling mechanism. Both classes promote GH release in preclinical models but operate through different receptor systems, which is the mechanistic basis for studying their combination in research blends. Researchers select between these classes based on which receptor system is the variable under investigation.

How does IGF-1 LR3 differ mechanistically from GHRH analogs like Sermorelin or Tesamorelin?

IGF-1 LR3 acts directly at insulin-like growth factor 1 receptors in peripheral tissues, bypassing the hypothalamic-pituitary axis entirely, whereas GHRH analogs stimulate upstream pituitary somatotrophs to release endogenous GH. This positional difference within the somatotropic cascade makes IGF-1 LR3 a distinct research tool for studying downstream growth factor receptor signaling independently of pituitary function. Researchers investigating receptor-level IGF-1 activity, rather than secretagogue dynamics, select IGF-1 LR3 specifically for that mechanistic separation.

What distinguishes Sermorelin from Tesamorelin as GH peptide research compounds?

Sermorelin is a 29-amino acid truncated fragment of endogenous GHRH representing the minimal sequence with retained GHRH receptor binding activity, while Tesamorelin is a full-length 44-amino acid GHRH analog incorporating structural modifications studied for enhanced stability relative to native GHRH. Both compounds act on the GHRH receptor class, but their structural differences have been the subject of preclinical comparisons examining receptor binding affinity and GH secretion profiles. Researchers select between them based on the structural variable under study and the half-life characteristics relevant to their model system.

Why do researchers use a CJC 1295 No DAC and Ipamorelin combination rather than either compound alone?

The CJC 1295 No DAC and Ipamorelin blend provides a dual-mechanism research preparation that engages both the GHRH receptor and the ghrelin receptor simultaneously, enabling preclinical investigation of synergistic or additive effects on GH secretion that are not observable with single-receptor stimulation alone. Preclinical literature has examined this type of two-receptor combination to characterize cooperative signaling dynamics between the two receptor systems. Researchers selecting this blend are typically studying the interaction between GHRH and ghrelin receptor pathways rather than isolating the contribution of a single receptor class.

What storage and handling considerations apply to growth hormone peptides in a laboratory setting?

Growth hormone peptides in this category are typically supplied as lyophilized powders requiring refrigerated or frozen storage prior to reconstitution, with reconstituted solutions generally maintained at 2 to 8 degrees Celsius and used within a defined window to preserve structural integrity. Peptide stability varies across compounds: shorter GHRH fragments such as Sermorelin may be more susceptible to degradation than structurally modified full-length analogs such as Tesamorelin, and IGF-1 LR3 requires particular attention to aggregation conditions during preparation. Researchers should consult the certificate of analysis and lot-specific documentation provided with each compound for authoritative storage parameters and reconstitution protocols.

Related Research Collections

Continue exploring

Peptides for Muscle GrowthPeptides for BodybuildingPeptides for Weight LossGLP-1 Peptides

All products are sold strictly for laboratory and scientific research use only. Not for human or animal consumption, diagnostic, or therapeutic use. Nothing on this page constitutes medical advice or a health claim.